Combining Toripalimab with Chemoradiotherapy for Cervical Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of toripalimab, an immunotherapy drug, when combined with definitive chemoradiotherapy (CCRT) for women with newly diagnosed locally advanced cervical cancer. The study aims to compare the outcomes of patients receiving this combination treatment against those receiving CCRT alone. Participants must be female, aged over 18, and diagnosed with specific stages of cervical cancer without distant metastasis. The trial seeks to improve treatment options for patients who have a poor prognosis with standard therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* more than 18 years old females
* had newly diagnosed and previously untreated locally advanced squamous cell carcinoma of the uterine cervix
* FIGO 2018 stage IB3 to IVA with no evidence of distant metastasis
* ECOG PS 0-1 without major organ failure
* signed informed consent voluntarily

Exclusion Criteria:

* previously suffered from immunodeficiency disorders
* had any condition that researchers believed to be associated with increased risk of treatment
* Previously received or currently receiving other PD-1 antibody treatments or other immunotherapies targeting PD-1/PD-L1

Where it's running

• Ruijin Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Haoping Xu — Ruijin Hospital
• Study coordinator: Dan Ou
• Email: od12341@rjh.com.cn
• Phone: 8618801970632

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short-course pelvic radiotherapy followed by CAPOX (capecitabine + oxaliplatin) and bevacizumab, with or without PD‑1 immunotherapy, for locally advanced rectal cancer.

  This trial tests whether adding a PD‑1 immunotherapy to short-course radiotherapy followed by CAPOX and bevacizumab helps adults with locally advanced rectal cancer get a higher complete response rate and fewer distant metastases.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07198165

• Toripalimab plus capecitabine after chemoradiotherapy for esophageal squamous cell carcinoma

  This trial will test whether giving toripalimab together with low‑dose capecitabine after definitive chemoradiotherapy helps people with locally advanced esophageal squamous cell carcinoma live longer and have fewer recurrences.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07177794

• Combining radiation therapy with targeted and immunotherapy for advanced kidney cancer

  This study is testing a new treatment that combines radiation therapy with two other medications to see if it helps people with advanced kidney cancer live longer without their disease getting worse.

  Recruiting Phase 2 Peking University First Hospital · Beijing, Beijing Municipality · NCT06889649

• Combining chemotherapy and immunotherapy for limited-stage small cell lung cancer

  This study is testing a new treatment that combines chemotherapy and immunotherapy to see if it can help people with limited-stage small cell lung cancer live longer and feel better.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06719700

• Nimotuzumab with Chemoradiotherapy for Esophageal Cancer

  This study is testing if a combination of a new antibody treatment, chemotherapy, and radiation can help older or malnourished patients with advanced esophageal cancer feel better and improve their chances of recovery.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06429839

• Combining immunotherapy and chemoradiotherapy for esophageal cancer treatment

  This study is testing if combining a new immunotherapy drug with traditional chemoradiotherapy can help people with advanced esophageal cancer have better treatment results.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Anyang, Henan and 2 other locations · NCT06421376

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.